难治性中重度溃疡性结肠炎的生物制剂治疗研究进展

被引：40

作者：

汪海潮 ^{[1
]}

叶晨 ^{[1
,2
]}

王晓蕾 ^{[1
]}

机构：

[1] 同济大学附属第十人民医院消化内科

[2] 苏州大学医学部

来源：

同济大学学报(医学版) | 2020年 / 41卷 / 01期

关键词：

溃疡性结肠炎; 生物制剂; 抗TNF-α类药物; 抗整合素制剂; JAK抑制剂;

D O I：

10.16118/j.1008-0392.2020.01.024

中图分类号：

R574.62 [结肠疾病];

学科分类号：

100201 [内科学];

摘要：

溃疡性结肠炎(ulcerative colitis, UC)是炎症性肠病的一种表现形式,可导致严重不良后果。临床常规用药包括氨基水杨酸制剂、糖皮质激素、免疫抑制剂,但仍有部分难治性中重度UC患者对常规治疗无效,需要转换至生物制剂治疗。目前用于临床治疗UC有效的生物制剂有3类(抗肿瘤坏死因子-α抗体、抗整合素α4β7制剂、肌酸激酶抑制剂)。本文旨在从药物作用机制、疗效及不良反应等方面总结各生物制剂治疗难治性中重度UC的特点,为临床用药提供参考。

引用

页码：136 / 140

页数：5

共 15 条

[1]

溃疡性结肠炎治疗进展 [J].

纪桂贤 ;

郑岳 .

中国误诊学杂志, 2011, 11 (13) :3048-3050

[2]

Golimumab for the treatment of ulcerative colitis [J].

Flamant, Mathurin ;

Paul, Stephane ;

Roblin, Xavier .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (07) :879-886

[3]

Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis [J].

McLean, Leon P. ;

Cross, Raymond K. .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (07) :833-842

[4]

Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis [J].

Toor, Kabirraaj ;

Druyts, Eric ;

Jansen, Jeroen P. ;

Thorlund, Kristian .

JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (06) :437-446

[5]

Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease [J].

Luthra, P. ;

Peyrin-Biroulet, L. ;

Ford, A. C. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (12) :1227-1236

[6]

Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs [J].

Thorlund, Kristian ;

Druyts, Eric ;

Toor, Kabirraaj ;

Mills, Edward J. .

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (05) :693-700

[7]

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial [J].

Vermeire, Severine ;

O'Byrne, Sharon ;

Keir, Mary ;

Williams, Marna ;

Lu, Timothy T. ;

Mansfield, John C. ;

Lamb, Christopher A. ;

Feagan, Brian G. ;

Panes, Julian ;

Salas, Azucena ;

Baumgart, Daniel C. ;

Schreiber, Stefan ;

Dotan, Iris ;

Sandborn, William J. ;

Tew, Gaik W. ;

Luca, Diana ;

Tang, Meina T. ;

Diehl, Lauri ;

Eastham-Anderson, Jeffrey ;

De Hertogh, Gert ;

Perrier, Clementine ;

Egen, Jackson G. ;

Kirby, John A. ;

van Assche, Gert ;

Rutgeerts, Paul .

LANCET, 2014, 384 (9940) :309-318

[8]

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis [J].

Sandborn, William J. ;

Feagan, Brian G. ;

Marano, Colleen ;

Zhang, Hongyan ;

Strauss, Richard ;

Johanns, Jewel ;

Adedokun, Omoniyi J. ;

Guzzo, Cynthia ;

Colombel, Jean-Frederic ;

Reinisch, Walter ;

Gibson, Peter R. ;

Collins, Judith ;

Jarnerot, Gunnar ;

Hibi, Toshifumi ;

Rutgeerts, Paul .

GASTROENTEROLOGY, 2014, 146 (01) :85-95

[9]

Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis.[J].Kristian Thorlund;Eric Druyts;Edward J. Mills;Richard N. Fedorak;John K. Marshall.Journal of Crohn's and Colitis.2014, 7

[10]

Adalimumab in ulcerative colitis: Ready for prime time [J].

Danese, Silvio .

DIGESTIVE AND LIVER DISEASE, 2013, 45 (01) :8-13

← 1 2 →